<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="94245">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02110355</url>
  </required_header>
  <id_info>
    <org_study_id>20120238</org_study_id>
    <nct_id>NCT02110355</nct_id>
  </id_info>
  <brief_title>A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma</brief_title>
  <official_title>A Phase 1b/2a Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 232 Combined With Trametinib and Dabrafenib or Trametinib in Adult Subjects With Metastatic Cutaneous Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1b/2a, open-label, sequential dose escalation, expansion study of AMG 232 in subjects
      with metastatic melanoma followed by a direct comparison of AMG 232, trametinib, and
      dabrafenib versus trametinib and dabrafenib alone.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>36 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Subject incidence of adverse events, dose limiting toxicities, and clinically significant changes in vital signs, weight, ECGs and clinical laboratory tests</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Tumor Response</measure>
    <time_frame>36 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Duration of overall response and duration of stable disease measured by CT or MRI and assessed per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">146</enrollment>
  <condition>Advanced Malignancy</condition>
  <condition>Advanced Solid Tumors</condition>
  <condition>Cancer</condition>
  <condition>Oncology</condition>
  <condition>Oncology Patients</condition>
  <condition>Tumors</condition>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>AMG 232, Trametinib, Dabrabenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1 and 2 arm 1 and Part 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AMG 232, Trametinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1 and 2 arm 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trametinib and Dabrafenib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Part 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 232</intervention_name>
    <description>Given as an oral tablet in escalating doses</description>
    <arm_group_label>AMG 232, Trametinib, Dabrabenib</arm_group_label>
    <arm_group_label>AMG 232, Trametinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trametinib</intervention_name>
    <description>Trametinib is an anti-cancer agent</description>
    <arm_group_label>AMG 232, Trametinib, Dabrabenib</arm_group_label>
    <arm_group_label>AMG 232, Trametinib</arm_group_label>
    <arm_group_label>Trametinib and Dabrafenib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabrafenib</intervention_name>
    <description>Dabrafenib is an anti-cancer agent</description>
    <arm_group_label>AMG 232, Trametinib, Dabrabenib</arm_group_label>
    <arm_group_label>Trametinib and Dabrafenib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must have histologically or cytologically confirmed metastatic cutaneous
             melanoma

          -  Able to swallow and retain orally administered medicaiton

          -  Adequate hematological, renal, hepatic, and coagulation laboratory assessments

        Exclusion Criteria:

          -  Clinically significant bleeding within 4 weeks of screening

          -  Current use of warfarin, factor Xa inhibitors, and direct thrombin inhibitors

          -  Infection requiring anti-infective treatments within 1 week of study enrollment

          -  Anti-tumor therapy

          -  Major surgery within 28 days
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amgen Call Center</last_name>
    <phone>866-572-6436</phone>
  </overall_contact>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 8, 2014</lastchanged_date>
  <firstreceived_date>April 8, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic melanoma</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
